Preclinical Evaluation of the Pan-FGFR Inhibitor LY2874455 in FRS2-Amplified Liposarcoma

Background: FGFR inhibition has been proposed as treatment for dedifferentiated liposarcoma (DDLPS) with amplified FRS2, but we previously only demonstrated transient cytostatic effects when treating FRS2-amplified DDLPS cells with NVP-BGJ398. Methods: Effects of the more potent FGFR inhibitor LY287...

Descripción completa

Detalles Bibliográficos
Autores principales: Hanes, Robert, Munthe, Else, Grad, Iwona, Han, Jianhua, Karlsen, Ida, McCormack, Emmet, Meza-Zepeda, Leonardo A., Stratford, Eva Wessel, Myklebost, Ola
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6406403/
https://www.ncbi.nlm.nih.gov/pubmed/30795553
http://dx.doi.org/10.3390/cells8020189

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6406403/
https://www.ncbi.nlm.nih.gov/pubmed/30795553
http://dx.doi.org/10.3390/cells8020189

Ejemplares similares